PharVision Advisers LLC Invests $211,000 in Astrana Health, Inc. (NASDAQ:ASTH)

PharVision Advisers LLC acquired a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,695 shares of the company’s stock, valued at approximately $211,000.

Other large investors also recently modified their holdings of the company. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Astrana Health during the 4th quarter worth about $40,000. Quarry LP boosted its stake in shares of Astrana Health by 35.5% during the 4th quarter. Quarry LP now owns 1,799 shares of the company’s stock worth $57,000 after buying an additional 471 shares during the last quarter. KBC Group NV boosted its stake in shares of Astrana Health by 108.4% during the 4th quarter. KBC Group NV now owns 2,530 shares of the company’s stock worth $80,000 after buying an additional 1,316 shares during the last quarter. US Bancorp DE boosted its stake in shares of Astrana Health by 3,880.0% during the 4th quarter. US Bancorp DE now owns 4,776 shares of the company’s stock worth $151,000 after buying an additional 4,656 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its stake in shares of Astrana Health by 21.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 7,075 shares of the company’s stock worth $223,000 after buying an additional 1,273 shares during the last quarter. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Bank of America cut their target price on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Barclays assumed coverage on shares of Astrana Health in a research note on Tuesday, April 1st. They issued an “equal weight” rating and a $36.00 target price for the company. Truist Financial cut their target price on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. Stifel Nicolaus cut their target price on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Finally, Robert W. Baird cut their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.29.

Astrana Health Stock Down 2.9%

Astrana Health stock opened at $24.47 on Friday. The stock has a market cap of $1.37 billion, a P/E ratio of 18.82, a P/E/G ratio of 1.37 and a beta of 1.00. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a twelve month low of $23.12 and a twelve month high of $63.20. The company’s 50-day moving average price is $30.50 and its two-hundred day moving average price is $34.63.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.09). The company had revenue of $620.39 million during the quarter, compared to the consensus estimate of $628.11 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm’s revenue was up 53.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 earnings per share. As a group, analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.